Clinical trials: Schizophrenia and Disorders With Psychotic Features
Psychosis
Psychosis TMS Study
The main goal of this study is to investigate the neural mechanisms of working memory function in patients with early psychosis using Transcranial Magnetic Stimulation (TMS) in conjunction with functional MRI.
- Trial name
- NCT05857137
- Testing
- Active TMS
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizoaffective Disorder
Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder
This is a six week, double blind,placebo controlled study for patients with schizophrenia or schizoaffective disorder treated with an atypical antipsychotic for at least two months.
- Trial name
- NCT00373672
- Testing
- armodafinil (Nuvigil)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Northwestern University
Schizophrenia
The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics
The purpose of this study is to assess if AZD8529 improves performance on neurobehavioral probes of attention, working memory and affective reactivity in patients with schizophrenia.
- Trial name
- NCT00986531
- Testing
- AZD8529
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Schizophrenic Disorders
Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
This pilot trial in Finland is designed to evaluate in a randomized fashion change of agitation in acute schizophrenic patients (Schizophrenia or Schizoaffective psychosis or Schizophreniformic psychosis)Diagnostic and…
- Trial name
- NCT00660595
- Testing
- Quetiapine, Risperidone
- Where
- 4 sites in Finland
- Volunteers
- 29 people
- Sponsor
- AstraZeneca
Psychosis
Effect of N-acetylcysteine on Brain Glutamate
A double-blind, placebo controlled, crossover study to determine whether a single dose of N-acetylcysteine (a nutritional supplement) can reduce brain glutamate levels in patients with a psychotic disorder.
- Trial name
- NAC (NCT02483130)
- Testing
- N-Acetylcysteine
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- King's College London
Schizophrenia
Safety and Efficacy of MP-214 in Patients With Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of MP-214 relative to placebo in patients with acute exacerbation of schizophrenia.
- Trial name
- NCT01625000
- Testing
- MP-214 3mg, MP-214 6mg, MP-214 9mg
- Where
- 3 sites in Japan, South Korea and 1 more
- Volunteers
- 512 people
- Sponsor
- Tanabe Pharma Corporation
Schizophrenia, Schizoaffective Disorder
Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics
Because ziprasidone has not been extensively studied and is not widely accepted in the severely mentally ill in State hospitals this study aims to demonstrate its effectiveness and relative lack of side effects.
- Trial name
- NCT00458211
- Testing
- ziprasidone
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Bronx Psychiatric Center
Psychotic Disorders
Implementation of Family Involvement for Persons With Psychotic Disorders.
This study will develop and evaluate a complex intervention to implement guidelines on family involvement for patients with psychotic disorders (F20-29 in International Classification of Diseases ICD-10) in community mental…
- Trial name
- IFIP (NCT03869177)
- Testing
- Implementation support program
- Where
- 15 sites in Norway
- Volunteers
- 460 people
- Sponsor
- University of Oslo
Schizophrenia
Childhood Trauma in Schizophrenia: Exploration of Links Between Gene Expression, Cerebral Morphology and Symptomatology
Childhood trauma is known as a vulnerability factor in schizophrenia. In healthy volunteers, these adversities are linked to a decrease of grey matter of the brain, similar to those observed in schizophrenia.
- Trial name
- SCHIZO'TRAUMA (NCT03355781)
- Testing
- magnetic resonance imaging (MRI), Blood sample, Clinical psychiatric evaluation
- Where
- France
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Psychosis
Mentalization Based Treatment (MBT) in Help Seeking Youths With a Clinical High-Risk Condition for Psychosis (CHR-P)
The primary objective of this study is to evaluate the efficacy of Mentalization-Based Treatment (MBT) combined with Need-Based Clinical Interventions (NBCI) compared to NBCI alone, on CHR-P diagnostic statuses and symptom…
- Trial name
- MBT-Psychosis (NCT07093671)
- Testing
- MBT + NBCI
- Where
- Switzerland
- Volunteers
- 212 people
- Sponsor
- Marco Armando
Schizophrenia, Schizoaffective Disorder
A Randomised Controlled Trial of Coenzyme Q10 in Patients With Schizophrenia and Schizoaffective Disorder
The study is a randomised placebo controlled trial of Coenzyme Q10 (CoQ10) vitamin supplementation in a sample of patients with schizophrenia or schizoaffective disorder.
- Trial name
- NCT03576911
- Testing
- Coenzyme Q10
- Where
- Ireland
- Volunteers
- 72 people
- Sponsor
- University of Dublin, Trinity College
Mental Disorders, Severe
Measuring Development of Brain Responses to Vocal Sounds in Babies of Mums With Mental Illness
CAPRI-Voc examines the differences in how speech and environmental sounds are processed in the infant brain as they grow from 9 to 12 months.
- Trial name
- CAPRI-Voc (NCT04350294)
- Where
- United Kingdom
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Schizophrenia
Ziprasidone in Early Onset Schizophrenia Spectrum Disorders
This is an open trial of ziprasidone (ZIP) in children and adolescents. It is designed to provide pilot data on the magnitude of ZIP's antipsychotic effects in psychotic youth, dosing ranges, acute safety, and tolerability.
- Trial name
- ZEOSS (NCT01006551)
- Testing
- Ziprasidone
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia
"Manual Dexterity and Oculomotor Control in Schizophrenia"
The investigators recently showed that visuomotor integration was significantly altered in schizophrenic patients during: (i) a grip force task (Teremetz et al., 2014), and (ii) a saccadic paradigm (oculomotor task)(Amado et al.…
- Trial name
- MADOCS (NCT02826629)
- Testing
- Manual dexterity, Oculomotor movements, TMS coupled to EMG recording
- Where
- 2 sites in France
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier St Anne
Schizophrenia; Psychosis, Cognitive Impairment
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
Schizophrenia is a long-lasting and serious mental health disorder that affects about 1% of people worldwide. It can cause symptoms such as hallucinations and delusions (called positive symptoms), confused or disorganized…
- Trial name
- SHINE (NCT07084831)
- Testing
- Xanomeline/trospium
- Where
- 16 sites in Austria, Belgium and 8 more
- Sponsor
- European Group for Research In Schizophrenia
Bipolar Disorder, Affective Disorders, Psychotic
A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I Disorder
The purpose of this study is to determine the safety and efficacy of topiramate in adolescents with manic or mixed episodes of Bipolar I Disorder.
- Conditions
- Bipolar Disorder, Affective Disorders, Psychotic, Mood Disorders, Mental Disorders
- Trial name
- NCT00035802
- Testing
- Topiramate
- Volunteers
- 13 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Novel Candidate Genes for Treatment Response to Antipsychotics in Schizophrenia
Schizophrenia is a severe and chronic mental disorder. The lifetime risk of schizophrenia is around 1%. Its course is chronic and frequently disabling. The keystone of schizophrenia treatment is antipsychotic medications.
- Trial name
- GEXANT (NCT02205437)
- Where
- Spain
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Schizophrenia, Nicotine Addiction
Effects of rTMS on Cigarette Smoking and Cognition in Schizophrenia
Cigarette smoking rates are extremely high in persons with schizophrenia and this increases the risk of disease and death due to tobacco-related disorders.
- Trial name
- rTMSsmokelab (NCT01523730)
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- Canada
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia
Part 1 of the study will assess the enhancement of task-related brain activation (BOLD response) in key brain areas in schizophrenia during the performance of working memory, episodic memory and visual activation tasks as…
- Trial name
- NCT00825539
- Testing
- AQW051
- Where
- 7 sites in United States
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia
Neurobiological Effects of Oxytocin in Schizophrenia
22 male patients with schizophrenia and 22 male healthy volunteers will be included in the study. Subjects who meet the inclusion and exclusion criteria for the study will be recruited.
- Trial name
- NCT04177719
- Testing
- Oxytocin
- Where
- India
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health and Neuro Sciences, India
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.